Business
Hoth Therapeutics HT-001 Interim Results First-in-Class Topical Therapy Preserves Cancer Treatment While Resolving Dermatologic Side Effects
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company developing targeted therapies for rare and serious inflammatory conditions, today announced that its investigational candidate HT-001 met the primary efficacy endpoint in at least one metric in 100% of patients in its ongoing Phase 2a clinical study (CLEER-001) evaluating treatment for epidermal growth factor receptor inhibitor (EGFRI)-induced cutaneous toxicities.
About this update from Hoth Therapeutics, Inc.
[{"type":"text","content":"Hoth Therapeutics' HT-001 Achieves 100% Response Rate in at least one endpoint in Phase 2a Trial in PK Patients for EGFR Inhibitor-Related Skin Toxicities.","length":169,"tagName":"p","attribs":{}},{"type":"text","content":"Hoth Therapeutics will host a Key Opinion Leader (KOL) event on, at 3:30PM EST to highlight recent clinical progress with HT-001, a novel topical therapeutic developed to address EGFR inhibitor-induced skin toxicities in cancer patients. This event will feature insights from derm-oncology and dermatology specialists Jonathan Hale Zippin M.D., Ph.D., and Adam Friedman M.D., F.A.A.D., who will present interim results from the ongoing Phase 2 trial and discuss how HT-001 could redefine supportive care standards for oncology patients. Access/join the event through the following link: https://zoom.us/j/91353016981.","length":653,"tagName":"p"},{"type":"text","content":"Phase 2a Trial Highlights (CLEER-001)","length":37,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"100% of enrolled patients in open-label cohort achieved at least one primary endpoint of clinical dermatologic improvement","length":122,"tagName":"p"}]},{"val":[{"type":"text","content":"Over 65% reported reductions in pain and pruritus (itching)","length":59,"tagName":"p"}]},{"val":[{"type":"text","content":"0% required dose reduction or discontinuation of their EGFRI therapy.","length":69,"tagName":"p"}]},{"val":[{"type":"text","content":"Topical therapy was well tolerated with no serious adverse events.","length":66,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":316,"olType":false},{"type":"text","content":"NEW YORK, June 24, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company developing targeted therapies for rare and serious inflammatory conditions, today announced that its investigational candidate HT-001 met the primary efficacy endpoint in at least one metric in 100% of patients in its ongoing Phase 2a clinical study (CLEER-001) evaluating treatment for epidermal growth factor receptor inhibitor (EGFRI)-induced cutaneous toxicities.","length":500,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/Hoth Therapeutics Inc.)","displaySize":"","headline":null,"caption":"(PRNewsfoto/Hoth Therapeutics I...